Skip to content
  • News & Events
    • Press & Media
  • Culture
    • Careers
  • Partnering
  • Investors
  • Contact
Menu
  • News & Events
    • Press & Media
  • Culture
    • Careers
  • Partnering
  • Investors
  • Contact
  • Science
    • Barriers to Treatment in the Liver
    • Barriers to Treatment in the Pancreas
    • Overcoming Immunosuppression
    • Overcoming Intratumoral Pressure
    • Publications & Presentations
  • Platform
    • Drug Delivery Technology
  • Pipeline
    • Candidate SD-101
  • Clinical Trials
  • For Patients
  • About
Menu
  • Science
    • Barriers to Treatment in the Liver
    • Barriers to Treatment in the Pancreas
    • Overcoming Immunosuppression
    • Overcoming Intratumoral Pressure
    • Publications & Presentations
  • Platform
    • Drug Delivery Technology
  • Pipeline
    • Candidate SD-101
  • Clinical Trials
  • For Patients
  • About
Menu
  • Science
    • Barriers to Treatment in the Liver
    • Barriers to Treatment in the Pancreas
    • Overcoming Immunosuppression
    • Overcoming Intratumoral Pressure
    • Publications & Presentations
  • Platform
    • Drug Delivery Technology
  • Pipeline
    • Candidate SD-101
  • Clinical Trials
  • For Patients
  • About
  • News & Events
    • Press & Media
  • Culture
    • Careers
  • Partnering
  • Investors
  • Contact
Interactive scientific illustration of the cell types with the tumor microenvironment where a reopened blood vessel allows a drug to diffuse into the tissue.
Myeloid-Derived Suppressor cells (MDSCs)

Immunosuppressive MDSCs are recruited to the tumor microenvironment. TLR9 agonists have been shown to reprogram and eliminate MDSCs, reducing their immunosuppressive effects.6 1 of 4
  • « Previous
  • Next »
Natural Killer (NK) Cells

In tumors, NK cells are suppressed through various pathways but have shown reactivation upon TLR9 stimulation.6 2 of 4
  • « Previous
  • Next »
Toll-Like Receptor 9 (TLR9) Agonists

TLR9 agonists have the potential to activate the immune system and promote anti-tumor activity through activation and modulation of immune cells. 1–5 3 of 4
  • « Previous
  • Next »
Plasmacytoid Dendritic Cells (pDCs)

pDCs are suppressed in the tumor microenvironment (TME) but have shown reactivation through TLR9.6 4 of 4
  • « Previous
  • Next »
  • List Item #1
  • List Item #1
  • List Item #1
© 2023 TriSalus Life Sciences, Inc. All rights reserved
  • Privacy Policy
  • Compliance
  • Terms of Use
Linkedin Twitter
Linkedin Twitter
© 2023 TriSalus Life Sciences, Inc.
All rights reserved
  • Privacy Policy
  • Compliance
  • Terms of Use

IMPORTANT NOTICE

You are now leaving the Trisalus life Sciences corporate website.

We encourage you to read and evaluate terms of use, privacy, security and other similar policies of the destination site as they may differ from TriSalus’ standards.

Third Party Sites

TriSalus assumes no responsibility nor does it control, endorse or guarantee any aspect of your use of any third party sites. Additionally, the presence of this link does not imply the third party site’s endorsement of TriSalus or this website.

Thank you for visiting our site.

YES
CANCEL